Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 2 (3)

Trial Status

Active Not Recruiting2
Not Yet Recruiting2
Recruiting1
Enrolling By Invitation1

Clinical Trials (6)

Showing 6 of 6 trials
NCT07199569Phase 2Active Not RecruitingPrimary

Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells

NCT07342829Not Yet RecruitingPrimary

Prospective Follow-up After MVA-BN Booster Vaccination

NCT07253675Phase 2Not Yet RecruitingPrimary

Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo

NCT06549530Phase 2Active Not RecruitingPrimary

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

NCT07067723Enrolling By InvitationPrimary

Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part2)

NCT06840860RecruitingPrimary

Epidemiological and Pathophysiological Insights Through a Cross-sectional Survey (EPIC)

Showing all 6 trials

Research Network

Activity Timeline